Chain Drug Review - Lilly Ups Support for Evista
January 7th, 2009 INDIANAPOLIS — Eli Lilly and Co. is providing additional support for Evista, its osteoporosis preventive, by reorganizing its pharmaceutical sales force.
Evista, known generically as raloxifene hydrochloride, is marketed for the prevention of osteoporosis in postmenopausal women.
…
Customer Interaction Solutions - MatchLogic Enhances eVista
January 2nd, 2009MatchLogic, Inc. announced the Latest version of its relationship marketing application, eVista 3.0. Designed specifically for marketers, this release is intended to assist companies in better managing their customer interactions and to enabl…
Oncology Nursing Forum - Tablets curb breast cancer risk
December 31st, 2008The (FDA) approved raloxifene hydrochloride tablets (Evista[R], Eli Lilly and Company) to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer. Evista, an oral tablet, is a selective estrogen receptor modulator and should not be used by women with a high risk for blood clots. For more information on Evista, visit www.evista.com.
Related Results
…
Chain Drug Review - Evista granted priority review
December 29th, 2008Eli Lilly and Co. says that the FDA has granted a priority review for the supplemental new drug application for an osteoporosis indication for Evista. The drug has been on the market since January 1998 for use in preventing osteoporosis in postmeno…
Chain Drug Review - Marketing of Lilly’s Evista investigated
December 22nd, 2008 WASHINGTON — The United States Department of Justice is investigating the way Eli Lilly and Co. is marketing its drug Evista.
The criminal inquiry, which is being conducted by the Justice Department’s Office of Consumer Litigation in cooperation with the U.S. attorney’s office in Indianapolis, is investigating whether Lilly improperly promoted Evista for the prevention of breast cancer.
While gro…
Medical Update - Lilly’s Evista builds bone
December 19th, 2008Although hormone replacement therapy (HRT) is good for bones, recent research from the national Women’s Health Initiative study shows that HRT can increase the risk of breast cancer, heart attacks, and strokes. Dr. Jacques Rossouw, acting director of the WHI, recommends that women who are concerned about osteoporosis look into safer, effective alternatives to hormon…
Online Canadian Pharmacy: Providing Competitive Pricing On Medications
December 17th, 2008The cost of prescription drugs in different parts of the world have been rising rapidly leaving many uninsured and underinsured people with no reasonable way to incur their needed medications. With the rise of online Canadian drug pharmacy, buying prescription drugs online has become a quick and easy job. Now one can easily afford to buy prescri…
New Weapons to Fight Osteoporosis
December 12th, 2008 The bones of older women often get more and more brittle because they are
becoming less and less dense. Osteoporosis is the disease name for this
process, and people who suffer from it break bones more easily than normal.
For many years, women reaching menopause…
Canadadrugpharmacy.com: A Name you can trust-Print
December 8th, 2008The urge to deliver the best Canadian drugs gives the birth of innumerable pharmacies till date. Now, as the competition is getting tougher day by day, pharmaceutical companies are trying hard to survive by keeping originality of their medicines and offering them at an affordable rate. …
Healthfacts - Media hype the new findings for Evista as an anti-breast cancer drug
December 5th, 2008Initial results from a government-sponsored study indicate that the osteoporosis drug raloxifene (brand name: Evista) may protect against breast cancer. The study compared it against an older anti-breast cancer drug, tamoxifen (…

